Patent US5219328A successfully refreshed from Google Patents.
US5219328A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fibrin sealant delivery method
Assignee: Artivion Inc
•
Filing: 1990-01-03
•
Granted: 1993-06-15
•
Expires: 2010-01-03
Abstract
Abstract The present invention relates to a method for the formulation of fibrin sealant in a single delivery system. The method involves mixing a fibrinogen/Factor XIII precipitate solution with thrombin under conditions such that thrombin clotting activity is inhibited and said mixture is applied to a body site under conditions which activate the thrombin to convert fibrinogen into fibrin sealant. A single device, syringe or container, can be used to apply the fibrin sealant formulation.
Inventors
- 👤 Brenda S. Morse
- 👤 A. Denise Turner
- 👤 Robert T. McNally
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:49
CPC Classifications
A; A61; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/106; A61B; A61B17/00; A61B17/00491; A61P; A61P7/00; A61P7/04; A61B2017/00495; A61B17/22; A61B2017/22082
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
86 words
A method of effecting the formation of fibrin sealant at a body site comprising: i) mixing, in a container means, an aqueous solution comprising fibrinogen, Factor XIII and mature thrombin under conditions such that thrombin clotting activity is inhibited; and ii) applying a preparation resulting from step (i) to said body site under conditions such that thrombin clotting activity is restored and said fibrin sealant is formed; wherein step (i) is carried out at a pH of less than 5.5, whereby thrombin clotting activity is inhibited.
Claim 2
Independent Claim
86 words
A method of effecting the formation of fibrin sealant at a body site comprising: i) mixing, in a container means, an aqueous solution comprising fibrinogen, Factor XIII and mature thrombin under conditions such that thrombin clotting activity is inhibited; and ii) applying a preparation resulting from step (i) to said body site under conditions such that thrombin clotting activity is restored and said fibrin sealant is formed; wherein step (i) is carried out at a pH of less than 5.5, whereby thrombin clotting activity is inhibited.
Claim 3
Dependent Claim
28 words
The method according to claim 1 wherein, in step (ii), the pH of said preparation resulting from step (i) is increased such that thrombin clotting activity is restored.
Claim 4
Dependent Claim
34 words
The method according to claim 2 wherein the pH of said preparation resulting from step (i) is increased upon contact of said preparation with body fluids of said patient present at said body site.
Claim 5
Dependent Claim
31 words
The method according to claim 2 wherein, in step (ii), the pH of said preparation resulting from step (i) is increased upon contact with a buffered capable of increasing the pH.
Claim 6
Independent Claim
90 words
A method of effecting the formation of fibrin sealant at a body site comprising: i) mixing, in a container means, an aqueous solution comprising fibrinogen, Factor XIII and mature thrombin under conditions such that thrombin clotting activity is inhibited; and ii) applying a preparation resulting from step (i) to said body site under conditions such that thrombin clotting activity is restored and said fibrin sealant is formed; wherein said solution of step (i) includes an amount of a photosensitive inhibitor of thrombin clotting activity sufficient to inhibit thrombin clotting activity.
Claim 7
Independent Claim
90 words
A method of effecting the formation of fibrin sealant at a body site comprising: i) mixing, in a container means, an aqueous solution comprising fibrinogen, Factor XIII and mature thrombin under conditions such that thrombin clotting activity is inhibited; and ii) applying a preparation resulting from step (i) to said body site under conditions such that thrombin clotting activity is restored and said fibrin sealant is formed; wherein said solution of step (i) includes an amount of a photosensitive inhibitor of thrombin clotting activity sufficient to inhibit thrombin clotting activity.
Claim 8
Dependent Claim
34 words
The method according to claim 5 wherein, in step (ii), said preparation resulting from step (i) is irradiated with light of a wavelength that inactivates said photosensitive inhibitor, whereby thrombin clotting activity is restored.
References Cited (Backward Citations)
US2533004A
Cited
US2492458A
Cited
US3723244A
Cited
US4265233A
Cited
US4377572A
Cited
US4359049A
Cited
US4359463A
Cited
US4453939A
Cited
US4442655A
Cited
US4427651A
Cited
US4631055A
Cited
US4655211A
Cited
US4627879A
Cited
US4735616A
Cited
US4696812A
Cited
DE3622642A1
Cited
US4902281A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-06-14 | 1996-12-14 | 1997-06-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-06-14 | 2000-12-14 | 2001-06-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-06-14 | 2004-12-14 | 2005-06-15 | $7700.00 | Window Closed / Lapsed |